Insider · CIK 0001943192

Cline Christopher R.

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001943192

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+20K sh	$17.44	+$349K	138,016
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−27.5K sh	$62.00	−$1.7M	110,543
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−20.7K sh	$62.61	−$1.3M	89,808
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,900 sh	$63.69	−$121K	87,908
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−400 sh	$65.31	−$26.1K	87,508
2026-09-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−20K sh	—	—	0
2026-09-02	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−642 sh	$66.37	−$42.6K	118,016
2026-05-06	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−310 sh	$43.95	−$13.6K	118,658
2026-05-05	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,181 sh	$46.65	−$102K	118,968
2026-05-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+4,250 sh	—	—	121,149
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsA Award	CHIEF FINANCIAL OFFICER	AAward	+8,500 sh	—	—	8,500
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsM Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−4,250 sh	—	—	4,250
2026-04-15	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,014 sh	$42.61	−$43.2K	116,899
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−9 sh	$41.07	−$369.63	125,152
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−7,239 sh	$41.93	−$304K	117,913
2026-04-13	TVTXTravere Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+14K sh	—	—	125,226
2026-04-13	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−65 sh	$28.85	−$1,875.25	125,161
2026-02-04	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,635 sh	$32.14	−$52.5K	111,336
2026-02-04	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−110 sh	$32.90	−$3,619	111,226
2026-02-03	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−7,242 sh	$32.12	−$233K	112,971
2026-01-31	TVTXTravere Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+28.1K sh	—	—	120,213
2026-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+75K sh	—	—	75,000
2025-12-01	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+20K sh	$16.23	+$325K	112,083
2025-12-01	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−20K sh	$35.01	−$700K	92,083
2025-12-01	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−20K sh	—	—	0
2025-09-04	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−119 sh	$19.71	−$2,345.49	92,083
2025-09-03	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−454 sh	$18.20	−$8,262.8	92,202
2025-08-27	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−470 sh	$17.31	−$8,135.7	92,656
2025-05-05	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,784 sh	$21.05	−$37.6K	93,126
2025-05-02	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+4,920 sh	—	—	94,910
2025-05-02	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsM Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−4,920 sh	—	—	4,920
2025-04-11	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−48 sh	$13.14	−$630.941	89,990
2025-02-03	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−5,192 sh	$20.12	−$104K	90,038
2025-01-31	TVTXTravere Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+21.5K sh	—	—	95,230
2025-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+58K sh	—	—	58,000
2025-01-22	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−865 sh	$18.94	−$16.4K	73,730
2024-09-09	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,490 sh	$11.52	−$28.7K	74,595
2024-09-05	TVTXTravere Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+6,750 sh	—	—	77,085
2024-09-04	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−514 sh	$9.51	−$4,887.78	70,335
2024-04-11	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−54 sh	$6.74	−$363.96	70,849
2024-02-01	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−3,818 sh	$8.53	−$32.6K	70,903
2024-01-31	TVTXTravere Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+25K sh	—	—	74,721
2024-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+65K sh	—	—	65,000
2024-01-23	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−853 sh	$9.07	−$7,735.345	49,721
2023-09-05	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−457 sh	$14.71	−$6,722.561	50,574
2023-05-10	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−455 sh	$16.59	−$7,548.45	51,031
2023-04-11	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−47 sh	$21.49	−$1,010.03	51,486
2023-02-01	TVTXTravere Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,588 sh	$21.75	−$34.5K	51,533
2023-01-31	TVTXTravere Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+20.3K sh	—	—	53,121
2023-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+54.5K sh	—	—	54,500

Recent filings

Accepted (ET)
Sep 174
Cline Christopher R.0001943192-26-000006
SEC(opens sec.gov)
Sep 34
Cline Christopher R.0001943192-26-000005
SEC(opens sec.gov)
May 64
Cline Christopher R.0001943192-26-000004
SEC(opens sec.gov)
Apr 154
Cline Christopher R.0001943192-26-000003
SEC(opens sec.gov)
Feb 54
Cline Christopher R.0001943192-26-000002
SEC(opens sec.gov)
Feb 34
Cline Christopher R.0001943192-26-000001
SEC(opens sec.gov)

Companies

Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICERTVTX

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300

SAN DIEGO, CA, 92130